# OnCo record paper-keynote-057-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-057-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-057-lancet-oncol-2021" ;
  schema:name "KEYNOTE-057: pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ"@en ;
  schema:description "In patients whose high-risk bladder cancer no longer responded to BCG and who could not or would not have their bladder removed, pembrolizumab cleared the disease in about four in ten, with a response lasting a year or more in roughly half of those."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-057-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(21)00147-9>, <https://pubmed.ncbi.nlm.nih.gov/34051177/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(21)00147-9> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Balar AV, Kamat AM, Kulkarni GS, et al." ;
  onco:cancers <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-057/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .